25 results
8-K
EX-10.1
ADPT
Adaptive Biotechnologies Corp
12 Sep 22
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
8:45am
or correspondence from any Regulatory Agency, comparable authority, or institutional review board or ethics committee requiring the termination, suspension
424B5
sbagc3qb6jinouy2bvy
16 Jul 20
Prospectus supplement for primary offering
4:26pm
424B5
qiwy2tl
14 Jul 20
Prospectus supplement for primary offering
5:01pm
DEF 14A
gwq1ureq04b71wlst0
24 Apr 20
Definitive proxy
4:15pm
10-K
qfb4lsdot5 55z5p
26 Feb 20
Annual report
4:53pm
424B4
jlode3lvneydc2mhvwp
24 Jan 20
Prospectus supplement with pricing info
4:49pm
DRS
a0ik0 gscym7b
9 Jan 20
Draft registration statement
12:00am
424B4
9guwf3
27 Jun 19
Prospectus supplement with pricing info
5:24pm